Secondary Logo

Journal Logo

May 2019 - Volume 42 - Issue 5
pp: 413-492

Experimental Therapeutics

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors

Shah, Hiral A.; Fischer, James H.; Venepalli, Neeta K.; More

American Journal of Clinical Oncology. 42(5):413-420, May 2019.

Soft Tissue

Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors

Shurell-Linehan, Elizabeth; DiPardo, Benjamin J.; Elliott, Irmina A.; More

American Journal of Clinical Oncology. 42(5):426-431, May 2019.


Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)

Song, Yong; Wu, Yi-Long; Cao, Le-Jie; More

American Journal of Clinical Oncology. 42(5):432-439, May 2019.




Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients

Mandato, Vincenzo D.; Torricelli, Federica; Palomba, Stefano; More

American Journal of Clinical Oncology. 42(5):472-480, May 2019.

Central Nervous System